Loading…
Elijah E. Cummings Lower Drug Costs Now Act
Legislative Progress
Introduced
September 19, 2019
Latest Action
September 8, 2020
Primary Sponsor
Frank Pallone, Jr.Democratic(NJ)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
96pct
355d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Elijah E. Cummings Lower Drug Costs Now Act This bill establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health. TITLE I--LOWERING PRICES THROUGH FAIR DRUG PRICE NEGOTIATION The bill requires the Department of Health and Human Services (HHS) to negotiate prices for certain drugs. (Under current law, HHS may not negotiate the prices of covered drugs under the Medicare prescription drug benefit.) Specifically, HHS must negotiate maximum prices for (1) insulin products; (2) with respect to 2023, at least 25 single-source, brand-name drugs that do not have generic competition and that are among either the 125 drugs that account for the greatest national spending or the 125 drugs that account for the greatest spending under the Medicare prescription drug benefit and Medicare Advantage (MA); (3) beginning in 2024, at least 50 such single-source, brand-name drugs; and (4) newly approved single-source, brand-name drugs that meet or exceed a specified price threshold and that HHS determines are likely to meet the spending criteria. The negotiated prices must be offered under Medicare and MA and may also be offered under private health insurance unless the insurer opts out. The negotiated maximum price may not exceed (1) 120% of the average price in Australia, Canada, France, Germany, Japan, and the United Kingdom; or (2) if such information is not available, 85% of the U.S. average manufacturer price. Drug manufacturers that fail to comply with the bill's negotiation requirements are subject to civil and tax penalties. TITLE II--MEDICARE PARTS B AND D PRESCRIPTION DRUG INFLATION REBATES The bill also requires drug manufacturers, subject to civil penalties, to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for covered drugs under Medicare that cost $100 or more and for which the average manufacturer price increases faster than inflation. TITLE III--PART D IMPROVEMENTS AND MAXIMUM OUT-OF-POCKET CAP FOR MEDICARE BENEFICIARIES The bill reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit. Additionally, prescription drug plan sponsors must allow certain beneficiaries to make coinsurance payments in periodic installments, in accordance with CMS requirements. TITLE IV--DRUG PRICE TRANSPARENCY Drug manufacturers must report, subject to civil penalties, specified information for certain drugs that cost $100 or more and that are covered under Medicare or Medicaid, based on the rate of price or spending increases. Among other things, manufacturers must report a qualifying price increase at least 30 days before the effective date of the increase; HHS must publish the information on its website the day the increase takes effect. TITLE V--PROGRAM IMPROVEMENTS FOR MEDICARE LOW-INCOME BENEFICIARIES The bill expands eligibility for certain premium and cost-sharing subsidies for low-income beneficiaries under the Medicare prescription drug benefit. For example, the bill (1) raises the maximum allowable income for beneficiaries to qualify, and (2) allows certain residents of U.S. territories to automatically qualify. TITLE VI--PROVIDING FOR DENTAL, VISION, AND HEARING COVERAGE UNDER THE MEDICARE PROGRAM The bill also expands Medicare coverage to include (1) dentures and dental and oral health services, including basic and major treatments (as determined by the CMS) as well as specified preventive and screening services; (2) hearing aids and hearing rehabilitation and treatment services; and (3) eyeglasses, contact lenses, and vision services, including routine eye examinations and contact lens fittings. TITLE VII--NIH, FDA, AND OPIOIDS FUNDING The bill provides additional funds for several public health programs. Among other things, the bill (1) provides specified funds for innovation projects at the National Institutes of Health through FY2030 and for innovation projects at the Food and Drug Administration through FY2029; and (2) establishes the Opioid Epidemic Response Fund to support HHS programs and initiatives, including the State Opioid Response Grant Program. Additionally, HHS must take a series of actions relating to health care administrative costs. Specifically, HHS must develop a strategy and take associated action to reduce unnecessary costs and administrative burdens in the health care system, including Medicare, Medicaid, and the private health-insurance market, by at least half over a period of 10 years. HHS must also award grants so that states may establish commissions targeting such costs. TITLE VIII--MISCELLANEOUS The bill also establishes and revises several other health care programs and requirements. For example, the bill (1) expands guaranteed issue rights with respect to Medigap policies (Medicare supplemental health-insurance policies); (2) provides specified funds for the Community Health Centers Fund through FY2025; (3) establishes grant programs to support mental health and trauma services in schools, as well as career development programs for health professionals; and (4) requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. Additionally, the CMS must issue regulations that require direct-to-consumer television advertisements for all covered drugs and biologics under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment. (On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency . The rule requires direct-to-consumer television advertisements for covered drugs and biologics under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect July 9, 2019; however, a federal court blocked implementation, citing a lack of statutory authority.)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (290)
Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
Read the first time. Placed on Senate Legislative Calendar under Read the First Time.
Received in the Senate.
Motion to reconsider laid on the table Agreed to without objection.
On passage Passed by the Yeas and Nays: 230 - 192 (Roll no. 682).
HousePassed/agreed to in House: On passage Passed by the Yeas and Nays: 230 - 192 (Roll no. 682).
HouseOn motion to recommit with instructions Failed by the Yeas and Nays: 196 - 226 (Roll no. 681).
HouseThe previous question on the motion to recommit with instructions was ordered without objection.
DEBATE - The House proceeded with 10 minutes of debate on the Upton motion to recommit with instructions. The instructions contained in the motion seek to require the bill to be reported back to the House with an amendment to change the effective date of the Act until the Secretary of Health and Human Services certifies that the implementation of the provisions in the bill are not projected to result in fewer new drug applications with respect to unmet medical needs and life saving cures.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2024 · fourth_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 H.R. 8467, Farm, Food, and National Security Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 4229, Reducing Drug Prices for Seniors Act. Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; National Institute of Standards and Technology (NIST) draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
Client expense: $1,800,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · fourth_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 H.R. 8467, Farm, Food, and National Security Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 4229, Reducing Drug Prices for Seniors Act. Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; National Institute of Standards and Technology (NIST) draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
2024 · third_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 H.R. 8467, Farm, Food, and National Security Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 4229, Reducing Drug Prices for Seniors Act. Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; National Institute of Standards and Technology (NIST) draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
2024 · second_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 H.R. 8467, Farm, Food, and National Security Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 4229, Reducing Drug Prices for Seniors Act. Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; National Institute of Standards and Technology (NIST) draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues.
2024 · first_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 3633, PREVENT HPV Cancers Act of 2023 H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7635, The 340B PATIENTS Act of 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2024 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms.
Mr. Upton moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H10223)
The House adopted the amendments en gross as agreed to by the Committee of the Whole House on the state of the Union.
The previous question was ordered pursuant to the rule.
The House rose from the Committee of the Whole House on the state of the Union to report H.R. 3.
UNFINISHED BUSINESS - The Chair announced that the unfinished business was on adoption of amendments, which were debated earlier and on which further proceedings had been postponed.
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Houlahan amendment No. 12.
POSTPONED PROCEEDINGS - At the conclusion of debate on the Cunningham amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. Roe (TN) demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Cunningham amendment No. 11.
POSTPONED PROCEEDINGS - At the conclusion of debate on the Luria amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. Walden demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Luria amendment No. 10.
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Finkenauer amendment No. 9.
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Axne amendment No. 8.
POSTPONED PROCEEDINGS - At the conclusion of debate on the Gottheimer amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. Gottheimer demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Gottheimer amendment No. 7.
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Kennedy amendment No. 6.
POSTPONED PROCEEDINGS - At the conclusion of debate on the O'Halleran amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. O'Halleran demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the O'Halleran amendment No. 5.
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Kennedy amendment No. 4.
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Peters amendment No. 3.
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Tonko amendment No. 2.
POSTPONED PROCEEDINGS - At the conclusion of debate on the Walden amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the noes had prevailed. Mr. Walden demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to the provisions of H.Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Walden amendment No. 1.
GENERAL DEBATE - The Committee of the Whole proceeded with one hour of further debate on H.R. 3.
The House resolved into Committee of the Whole House on the state of the Union for further consideration.
Considered as unfinished business. (consideration: CR H10129-10225; text: CR H10141-10167)
Committee of the Whole House on the state of the Union rises leaving H.R. 3 as unfinished business.
On motion that the Committee rise Agreed to by voice vote.
Mr. Scott (VA) moved that the Committee rise.
GENERAL DEBATE - The Committee of the Whole proceeded with four hours of general debate on H.R. 3.
The Speaker designated the Honorable Donald M. Payne, Jr. to act as Chairman of the Committee.
House resolved itself into the Committee of the Whole House on the state of the Union pursuant to H. Res. 758 and Rule XVIII.
The rule provides for consideration of H.R. 3, under a structured rule, with 4 hours of general debate. The rule provides for consideration of H.R. 5038 under a closed rule, with 1 hour of general debate. The rule provides for consideration of the conference report to accompany S. 1790 with 1 hour of debate.
Considered under the provisions of rule H. Res. 758. (consideration: CR H10096-10117)
Rules Committee Resolution H. Res. 758 Reported to House. The rule provides for consideration of H.R. 3, under a structured rule, with 4 hours of general debate. The rule provides for consideration of H.R. 5038 under a closed rule, with 1 hour of general debate. The rule provides for consideration of the conference report to accompany S. 1790 with 1 hour of debate.
Placed on the Union Calendar, Calendar No. 264.
Reported (Amended) by the Committee on Education and Labor. H. Rept. 116-324, Part III.
Congress.gov source codes: 5000, H12200
House Committee on Education and Labor Granted an extension for further consideration ending not later than Dec. 9, 2019.
Reported (Amended) by the Committee on Ways and Means. H. Rept. 116-324, Part II.
Congress.gov source codes: 5000, H12200
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-324, Part I.
Congress.gov source codes: 5000, H12200
Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 24 - 17.
Committee Consideration and Mark-up Session Held.
Ordered to be Reported (Amended) by the Yeas and Nays: 27 - 21.
Committee Consideration and Mark-up Session Held.
Subcommittee on Health Discharged.
Ordered to be Reported by the Yeas and Nays: 30 - 22.
Subcommittee Hearings Held.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| House |
| Markup by |
| October 22, 2019 |
| Education and the Workforce Committee | House | Markup by | October 17, 2019 |
| Energy and Commerce Committee | House | Markup by | October 17, 2019 |
| Education and the Workforce Committee | House | Referred to | September 19, 2019 |
| Ways and Means Committee | House | Referred to | September 19, 2019 |
| Energy and Commerce Committee | House | Referred to | September 19, 2019 |
| September 19, 2019 |
| Democratic |
| CA |
| Adam Smith | Democratic | WA |
| Adriano Espaillat | Democratic | NY |
| Al Lawson, Jr. | Democratic | FL |
| Alan S. Lowenthal | Democratic | CA |
| Alcee L. Hastings | Democratic | FL |
| Andy Kim | Democratic | NJ |
| Angie Craig | Democratic | MN |
| Ann M. Kuster | Democratic | NH |
| Anna G. Eshoo | Democratic | CA |
| Betty McCollum | Democratic | MN |
| Bobby L. Rush | Democratic | IL |
| Bradley Scott Schneider | Democratic | IL |
| Brian Higgins | Democratic | NY |
| Charlie Crist | Democratic | FL |
| Cheri Bustos | Democratic | IL |
| Chris Pappas | Democratic | NH |
| Colin Z. Allred | Democratic | TX |
| Cynthia Axne | Democratic | IA |
| Daniel T. Kildee | Democratic | MI |
| Danny K. Davis | Democratic | IL |
| Darren Soto | Democratic | FL |
| David J. Trone | Democratic | MD |
| David Loebsack | Democratic | IA |
| Dean Phillips | Democratic | MN |
| Debbie Dingell | Democratic | MI |
| Debbie Mucarsel-Powell | Democratic | FL |
| Debbie Wasserman Schultz | Democratic | FL |
| Diana DeGette | Democratic | CO |
| Donald M. Payne, Jr. | Democratic | NJ |
| Donald Norcross | Democratic | NJ |
| Donald S. Beyer, Jr. | Democratic | VA |
| Donna E. Shalala | Democratic | FL |
| Doris O. Matsui | Democratic | CA |
| Dwight Evans | Democratic | PA |
| Ed Case | Democratic | HI |
| Ed Perlmutter | Democratic | CO |
| Eleanor Holmes Norton | Democratic | DC |
| Eliot L. Engel | Democratic | NY |
| Elissa Slotkin | Democratic | MI |
| Emanuel Cleaver | Democratic | MO |
| Filemon Vela | Democratic | TX |
| Frederica S. Wilson | Democratic | FL |
| Grace Meng | Democratic | NY |
| Gregorio Kilili Camacho Sablan | Democratic | MP |
| Gregory W. Meeks | Democratic | NY |
| Gwen Moore | Democratic | WI |
| Hakeem S. Jeffries | Democratic | NY |
| Haley M. Stevens | Democratic | MI |
| Henry Cuellar | Democratic | TX |
| Jahana Hayes | Democratic | CT |
| James P. McGovern | Democratic | MA |
| James R. Langevin | Democratic | RI |
| Janice D. Schakowsky | Democratic | IL |
| Jared F. Golden | Democratic | ME |
| Jennifer Wexton | Democratic | VA |
| Jerry McNerney | Democratic | CA |
| Joaquin Castro | Democratic | TX |
| Joe Courtney | Democratic | CT |
| John A. Yarmuth | Democratic | KY |
| John B. Larson | Democratic | CT |
| John Garamendi | Democratic | CA |
| John P. Sarbanes | Democratic | MD |
| Joseph D. Morelle | Democratic | NY |
| Joyce Beatty | Democratic | OH |
| Judy Chu | Democratic | CA |
| Karen Bass | Democratic | CA |
| Kathy Castor | Democratic | FL |
| Katie Hill | Democratic | CA |
| Kim Schrier | Democratic | WA |
| Lisa Blunt Rochester | Democratic | DE |
| Lizzie Fletcher | Democratic | TX |
| Lois Frankel | Democratic | FL |
| Lucy McBath | Democratic | GA |
| Marc A. Veasey | Democratic | TX |
| Mary Gay Scanlon | Democratic | PA |
| Matt Cartwright | Democratic | PA |
| Max Rose | Democratic | NY |
| Michael F. Doyle | Democratic | PA |
| Mike Thompson | Democratic | CA |
| Nita M. Lowey | Democratic | NY |
| Norma J. Torres | Democratic | CA |
| Peter J. Visclosky | Democratic | IN |
| Peter Welch | Democratic | VT |
| Raul Ruiz | Democratic | CA |
| Richard E. Neal | Democratic | MA |
| Robert C. "Bobby" Scott | Democratic | VA |
| Salud O. Carbajal | Democratic | CA |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Sean Casten | Democratic | IL |
| Sean Patrick Maloney | Democratic | NY |
| Sharice Davids | Democratic | KS |
| Stephen F. Lynch | Democratic | MA |
| Steve Cohen | Democratic | TN |
| Steven Horsford | Democratic | NV |
| Susan Wild | Democratic | PA |
| Suzanne Bonamici | Democratic | OR |
| Sylvia R. Garcia | Democratic | TX |
| Theodore E. Deutch | Democratic | FL |
| Thomas R. Suozzi | Democratic | NY |
| Tim Ryan | Democratic | OH |
| Vicente Gonzalez | Democratic | TX |
| William R. Keating | Democratic | MA |
| HR 5688 |
116th |
| Related bill |
| HR 5357 | 116th | Related bill |
| HR 5281 | 116th | Related bill |
| HR 4835 | 116th | Related bill |
| HR 4768 | 116th | Related bill |
| HR 4676 | 116th | Related bill |
| HR 4675 | 116th | Related bill |
| HR 4669 | 116th | Related bill |
| HR 4666 | 116th | Related bill |
| HR 4665 | 116th | Related bill |
| HR 4663 | 116th | Related bill |
| HR 4661 | 116th | Related bill |
| HR 4650 | 116th | Related bill |
| HR 4649 | 116th | Related bill |
| HR 4633 | 116th | Related bill |
| HR 4629 | 116th | Related bill |
| HR 4619 | 116th | Related bill |
| HR 4618 | 116th | Related bill |
| HR 4455 | 116th | Related bill |
| HR 3398 | 116th | Related bill |
| HR 3347 | 116th | Related bill |
| HR 3343 | 116th | Related bill |
| HR 2296 | 116th | Related bill |
Client expense: $1,730,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $2,190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $3,010,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $2,190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Issues related to the Patent and Trademark Law Amendments Act (PL 96-517); FY-2023 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms.
Client expense: $1,940,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1418/S. 1844, Animal Drug User Fee Amendments of 2023 H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 4348, (117th Cong) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Anti-microbial Resistance; Vaccines; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2023 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; Animal Drug User Fee Reauthorization; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Step therapy requirements in commercial health plans; Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues Pharmacy Benefit Manager reforms.
Client expense: $2,130,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1418/S. 1844, Animal Drug User Fee Amendments of 2023 H.R. 1503/S. 1844, Prescription Information Modernization Act of 2023 H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, (117th Cong) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Anti-microbial Resistance; Vaccines; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; Animal Drug User Fee Reauthorization; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Step therapy requirements in commercial health plans; Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues.
Client expense: $2,980,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Medicare/Medicaid
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to Medicare Part B H.R. 2716, Consolidated Appropriations Act, 2023, provisions relating to Medicare Part D emergency use authorization coverage H.R. 5376, Build Back Better Act S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, Medicaid; Medicare; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; Prior authorization process under Medicare Advantage plans; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2023 Budget and Appropriations Legislation.
Client expense: $2,490,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3655, Vaccine Injury Compensation Modernization Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 S. 4760, (116th Congress) The PASTEUR Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Prescription Drug User Fees Act (P.L. 102-571); Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Animal Drug User Fee Act (P.L. 108-130); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023 Vaccine Injury Compensation Program.
Client expense: $2,490,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · third_quarter · Health Issues
CMS-9115-P Interoperability and Patient Access Final Rule HHS ONC RIN-0955-AA01 - 21st Century Cures Interoperability and Information Blocking Final Rule H.R. 3, Elijah E. Cummings Lower Drug Prices Now Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 (116th Congress) S. 2164, Lower Cost, More Cures Act of 2021 COVID-19 Response, including COVID-19 bills legislation implementation The Senate Amendment to H.R. 133, Consolidated Appropriations Act, 2021 (surprise billing legislation implementation) H.R. 19, Lower Cost, More Cures Act of 2021 Inflation Reduction Act of 2022 (HR 5376) Public Law No. 117-169 CMS-9908-IFC Surprise Billing, Part II; Interim Final Rule with Comment Period
Client expense: $1,220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2022 · third_quarter · Medicare/Medicaid
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to Medicare Part B H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Inflation Reduction Act of 2022, including provisions relating to drug pricing S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, Medicaid; Medicare; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; Medicare Part D COVID-19 therapeutic coverage issues Prior authorization process under Medicare Advantage plans; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2023 Budget and Appropriations Legislation.
Client expense: $1,080,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Inflation Reduction Act of 2022, including provisions relating to drug pricing H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel Isssues; Prescription Drug User Fees Act (P.L. 102-571); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.
Client expense: $1,080,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · second_quarter · Health Issues
CMS-9115-P Interoperability and Patient Access Final Rule HHS ONC RIN-0955-AA01 - 21st Century Cures Interoperability and Information Blocking Final Rule H.R. 3, Elijah E. Cummings Lower Drug Prices Now Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 (116th Congress) S. 2164, Lower Cost, More Cures Act of 2021 COVID-19 Response, including COVID-19 bills legislation implementation The Senate Amendment to H.R. 133, Consolidated Appropriations Act, 2021 (surprise billing legislation implementation) H.R. 19, Lower Cost, More Cures Act of 2021 Build Back Better Act (House and Senate) CMS-9908-IFC Surprise Billing, Part II; Interim Final Rule with Comment Period
Client expense: $1,240,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2022 · second_quarter · Health Issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel Isssues; Prescription Drug User Fees Act (P.L. 102-571); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.
Client expense: $2,610,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · second_quarter · Medicare/Medicaid
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to Medicare Part B H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, Medicaid; Medicare; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; Prior authorization process under Medicare Advantage plans; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2023 Budget and Appropriations Legislation.
Client expense: $2,610,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
Legislative Employer-sponsored health coverage - testing and vaccine distribution, COBRA subsidies, telehealth, primary care and worksite clinics and more comprehensive coverage of chronic disease prevention measures Further Extending Government Funding - short-term continuing resolution (CR- through February 18, 2022 - HSA Telehealth extension - H.R. 6119 Consolidated Appropriations Act, 2022 (CAA 2022) - Telehealth extension FY 2023 Budget Proposal - mental health, pandemic preparedness Build Back Better Act (BBBA) - H.R. 5376 - health care coverage and affordability issues, prescription drugs, paid family and medical leave, mental health parity penalties Healthy Competition for Better Care Act - S. 3139 Treat and Reduce Obesity Act - S. 596/H.R. 1577 Telehealth Expansion Act - S. 1704/H.R. 5981 FAMILY Act - H.R. 804/S.248 - Paid Family Leave Paid Family and Medical Leave American Families Plan - national comprehensive paid family and medical leave program Infrastructure Investment and Jobs Act (IIJA) - H.R. 3684 Affordable Insulin Now Act - S. 3700/H.R. 6833 Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act - draft legislation PREVENT Pandemics Act - S. 3799 Transparency of Hospital Billing Act - H.R. 8133 Consumer Choice of Care Act - H.R. 8134 Addressing Anticompetitive Contracting Clauses Act - H.R. 8135 Dependent Care Flexible Spending Accounts (FSAs) Health Flexible Spending Accounts (FSAs) Health Savings Accounts (HSAs) Quality, Cost & Transparency - Lower Health Care Costs Act (S. 1895, 116th Congress) Mental Health Matters Act - H.R. 7780 The Restoring Hope for Mental Health and Well-Being Act - H.R. 7666 Mental Health - Request for Information (RFI) - U.S. Senate Finance Committee Mental health parity Prescription drug legislation Elijah E. Cummings Lower Drug Costs Now Act - H.R. 3 Surprise billing regulations Healthy Future Task Force (House Republicans) - comments submitted to Affordability (lower costs) and Modernization (Telehealth expansion) Subcommittees Regulatory Treasury/IRS - proposed Regulations - Affordability Determination for Employer-Sponsored Family Health Coverage (Family Glitch) Federal Trade Commission (FTC) and Department of Justice (DOJ) - Request for Information (RFI) - recommendations for increasing competition in health care Departments of Health & Human Services (HHS), Labor and Treasury (the tri-agencies) - recommendations for forthcoming Health Plan Nondiscrimination Rules Department of Health & Human Services (HHS) - comments regarding health equity data reporting, hospital price transparency rules, and release of hospital safety data - Medicare Proposed IPPS Rule Federal Trade Commission (FTC) - Request for Information on Pharmacy Benefit Managers (PBMs) White House Executive Order - Continuing to Strengthen Americans Access to Affordable, Quality Health Coverage and related regulations on the premium tax credit under the ACA Treasury/IRS -Pre-Deductible Telehealth Care in High Deductible Health Plans HHS/Labor & Treasury (the tri-agencies) interim final regulations (IFR) on CAA requirements for group health plans and health insurers to report on prescription drug and health spending Executive Order - Promoting Competition in the American Economy Labor, Treasury & HHS (the tri-agencies) - public report issued on mental health parity compliance enforcement Mental health parity requirements for group health plans and insurers, including under the CAA Treasury/DOL/HHS - implementation of surprise billing provisions under the CAA - interim final regulations (IFR) part 1 and part 2 DOL - State All Payer Claims Database - Guidance, including Report by Advisory Committee under the CAA DOL/Treasury/HHS - transparency provisions under the CAA HHS - Enforcement of Hospital Price Transparency Rules Treasury/IRS - request for guidance on repurposing of welfare benefit fund assets ERISA uniformity High Deductible Health Plans (HDHPs) Health Savings Accounts (HSAs) State health care requirements affecting self-insured plans
Client expense: $433,084 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Equal Employment Opportunity Commission (EEOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2022 · first_quarter · Health Issues
CMS-9115-P Interoperability and Patient Access Final Rule HHS ONC RIN-0955-AA01 - 21st Century Cures Interoperability and Information Blocking Final Rule H.R. 3, Elijah E. Cummings Lower Drug Prices Now Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 (116th Congress) S. 2164, Lower Cost, More Cures Act of 2021 COVID-19 Response, including COVID-19 bills legislation implementation The Senate Amendment to H.R. 133, Consolidated Appropriations Act, 2021 (surprise billing legislation implementation) H.R. 19, Lower Cost, More Cures Act of 2021 Build Back Better Act (House and Senate) CMS-9908-IFC Surprise Billing, Part II; Interim Final Rule with Comment Period
Client expense: $1,370,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2022 · first_quarter · Medicare/Medicaid
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to Medicare Part B H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, Medicaid; Medicare; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2023 Budget and Appropriations Legislation.
Client expense: $2,120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, Advancing Emergency Preparedness Through One Health Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 FDA Emergency Use Authorization issues; COVID-19 Pandemic response; Cost and value of medicines; Drug importation; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Prescription Drug User Fee Authorization (PDUFA VII); Prescription Drug User Fees Act (P.L. 102-571); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.
Client expense: $2,120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
Legislative Employer-sponsored health coverage - testing and vaccine distribution, COBRA subsidies, telehealth, primary care and worksite clinics and more comprehensive coverage of chronic disease prevention measures Further Extending Government Funding - short-term continuing resolution (CR- through February 18, 2022 - HSA Telehealth extension - H.R. 6119 Consolidated Appropriations Act, 2022 (CAA 2022) - Telehealth extension FY 2023 Budget Proposal - mental health, pandemic preparedness Build Back Better Act (BBBA) - H.R. 5376 - health care coverage and affordability issues, prescription drugs, paid family and medical leave, mental health parity penalties Healthy Competition for Better Care Act - S. 3139 Treat and Reduce Obesity Act - S. 596/H.R. 1577 Telehealth Expansion Act - S. 1704/H.R. 5981 FAMILY Act - H.R. 804/S.248 - Paid Family Leave American Families Plan - national comprehensive paid family and medical leave program Infrastructure Investment and Jobs Act (IIJA) - H.R. 3684 Affordable Insulin Now Act - S. 3700/H.R. 6833 PREVENT Pandemics Act - S. 3799 Dependent Care Flexible Spending Accounts (FSAs) Health Flexible Spending Accounts (FSAs) Health Savings Accounts (HSAs) Quality, Cost & Transparency - Lower Health Care Costs Act (S. 1895, 116th Congress) Mental Health - Request for Information (RFI) - U.S. Senate Finance Committee Mental health parity Prescription drug legislation Elijah E. Cummings Lower Drug Costs Now Act - H.R. 3 Surprise billing regulations Healthy Future Task Force (House Republicans) - comments submitted to Affordability (lower costs) and Modernization (Telehealth expansion) Subcommittees Regulatory Departments of Health & Human Services (HHS), Labor and Treasury (the tri-agencies) - group health plan coverage of over the counter (OTC) COVID-19 tests without cost-sharing Treasury/IRS - proposed permanent ACA health coverage reporting relief White House Executive Order - Continuing to Strengthen Americans Access to Affordable, Quality Health Coverage and related regulations on the premium tax credit under the ACA Treasury/IRS -Pre-Deductible Telehealth Care in High Deductible Health Plans HHS/Labor & Treasury (the tri-agencies) interim final regulations (IFR) on CAA requirements for group health plans and health insurers to report on prescription drug and health spending Executive Order - Promoting Competition in the American Economy HHS - Comprehensive Plan for Addressing High Drug Costs Labor/HHS/Treasury - proposed regulations regarding air ambulance reporting for group health plans and insurers Labor, Treasury & HHS (the tri-agencies) - public report issued on mental health parity compliance enforcement Mental health parity requirements for group health plans and insurers, including under the CAA Treasury/DOL/HHS - implementation of surprise billing provisions under the CAA - interim final regulations (IFR) part 1 and part 2 DOL - State All Payer Claims Database - Guidance, including Report by Advisory Committee under the CAA EEOC - vaccine incentive and mandate guidance for employers DOL/Treasury/HHS - transparency provisions under the CAA HHS - Enforcement of Hospital Price Transparency Rules Provider nondiscrimination rules under the CAA and the ACA Treasury/IRS - request for guidance on repurposing of welfare benefit fund assets ERISA uniformity High Deductible Health Plans (HDHPs) Health Savings Accounts (HSAs) Federal Trade Commission (FTC)/Department of Justice (DOJ) - Request for Information (RFI) on Merger Enforcement State health care requirements affecting self-insured plans
Client expense: $338,574 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Equal Employment Opportunity Commission (EEOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2021 · fourth_quarter · Health Issues
H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 2061, Advancing Emergency Preparedness Through One Health Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. H.R. 8920/S. 4760, (116th Congress) The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 FDA Emergency Use Authorization issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; Package inserts and labeling issues; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.
Client expense: $1,500,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Medicare/Medicaid
H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019, provisions related to Medicare Part B S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, Medicaid; Medicare; Medicare Part B; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2022 Budget and Appropriations Legislation.
Client expense: $1,500,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Small Business
Tax Reform and Tax and Budget Policy Tax Cuts and Jobs Act (TCJA): Continue to express support for the permanency of various provisions of the TCJA including Section 199A, lower personal tax rates, expensing provisions and estate tax changes. Main Street Certainty Act, H.R. 1381/S. 480: Support passage to make permanent the 20% small business deduction in the Tax Cuts and Jobs Act. Stepped-up Basis: Opposed efforts to eliminate stepped-up basis, as included within the Sensible Taxation and Equity Promotion (STEP) Act in the Senate and House, H.R. 2286. Supported S. Amdt #3106 to S.Con Res. 14, the Fiscal Year 2022 Budget Resolution, introduced by Senator John Thune (R-S.D.) Expressed continued support for stepped-up basis. S. Con. Res. 14 - FY22 Budget Resolution: Opposed the legislation. Proposed Tax Increases Considered by House Ways and Means as Part of $3.5 Trillion Reconciliation Package: Opposed the proposals to raise rates on pass-throughs and C corporations, capping the Section 199A deduction, increases to the capital gains tax, imposition of capital gains at death, changes to TCJA death tax provisions, and corporate tax rates. Comprehensive Account Reporting of Financial and Bank Account Information to the IRS: Oppose Biden/U.S. Treasury reporting scheme, and efforts in the Congress to utilize such to pay for the $3.5 trillion spending package. PRO Act Tax Increase: Oppose efforts to include the PRO Act within an unemployment insurance reform measure in the $3.5 trillion package as a pay-for, which would mean higher taxes and costs for millions of small businesses. (The Wyden-Bennet proposal.) Affordable and Competitive Health Coverage Affordability/More Choices: Continue to urge members of Congress and the Administration to advance market-oriented reforms that will lower health coverage costs for small businesses and increase more flexible choices in the marketplace. Oppose efforts, generally, to impose new mandates and taxes that will add to small business costs and reduce access to health care. Price Controls on Drugs: Expressed opposition to efforts that place price controls on drugs either through Medicare negotiation, an international pricing mechanism, or drug importation. H.R. 3, the Lower Drug Costs Now Act of 2019: Oppose. Federal Government Procurement Escobar Amendment (#499) to the Rules Committee: Opposed the amendment. Regulation Expressed general concern to Congress and the Biden Administration about imposing new regulatory burdens on small businesses, and the impact during the fragile recovery period. Biden Executive Order on Competition: Expressed concern about the Promoting Competition in the American Economy Executive Order, as it is more about massive regulation than competition policy. COVID-19 Vaccine Mandate: Oppose efforts by the Administration and OSHA to oppose this mandate given the success of businesses working through this issue without government interference or a one-size-fits-all and punitive approach. PRO Act, H.R. 842/S.420: Oppose the Protecting the Right to Organize Act Consumer Financial Protection Commission Act, H.R. 4773: Support the legislation. Modern Worker Empowerment Act, H.R. 4069/S. 2973: Support the legislation. Fair and Open Competition Act, H.R. 1284/S. 403: Support the legislation. Privacy Legislation: Support a national framework for privacy that is inclusive and equitable to all industries. Comments to DOL to establish negotiated rulemaking committees to prepare proposed regulations for programs authorized under title IV of the Higher Education Act of 1965, as amended (HEA): Filed comments supporting an inclusive approach to all educational providers including online courses and models of learning. American Choice and Online Innovation Act, H.R. 3816: Opposed the legislation. Ending Platforms Monopolies Act, H.R. 3825: Opposed the legislation. Platform Competition and Opportunity Act, H.R. 3826: Opposed the legislation. Nomination and Appointments DOL Wage and Hour Nominee: Expressed opposition to the candidacy of David Weil as DOL Wage and Hour Administrator, and his Senate confirmation. SBA Deputy Administration: Expressed support to the U.S. Senate for the nomination of Dilawar Syed to the post of Deputy Administrator of the Small Business Administration (SBA).
Client expense: $30,000 · Firm income: Not reported
Government targets: Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · third_quarter · Health Issues
Maternal Mental Health - Black Maternal Health Momnibus Act of 2021 Hospital Site of Care Reforms - Two Midnight Rule, Hospital apathy to prioritize maternal mental health Mental Health - pandemic related education and telehealth Medicare Part D Reform - HR.3 and the Prescription Drug Pricing Reduction Act of 2020 21st Century Cures Discussion Draft v.2
Client expense: $275,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Health Issues
Issues related to HR 3 "Lower Drug Costs Now Act of 2019"; issues related to drug pricing; issues related to Drug Pricing in H.R.5376 "Build Back Better Act"; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to insulin pricing; issues related to funding for Pandemic influenza; issues related to Bipartisan Infrastructure Package; issues related to HR 550 "Immunization Infrastructure Modernization Act"; issues related to HR 3655 "Vaccine Injury Compensation Modernization Act"; issues related to RX to OTC switch; issues related to S.1132 "EPI Act"; issues related to HR 19 "Lower Costs, More Cures Act of 2021"; issues related Counterfeits in S.936 "INFORM Consumers Act"; issues related to Counterfeits in S.1843 "SHOP SAFE Act"; issues related to Pandemic Preparedness; issues related to Cures 2.0; issues related to Platform Technologies; issues related to Medicare Sequestration; issues related to Reconciliation; and issues related to Intellectual Property.
Client expense: $1,310,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Medicare/Medicaid
H.R. 1319, American Rescue Plan Act of 2021, Medicaid provisions and AMP Cap H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019, provisions related to Medicare Part B S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, Medicaid; Medicare Part B; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2022 Budget and Appropriations Legislation.
Client expense: $1,700,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Health Issues
H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 2061, Advancing Emergency Preparedness Through One Health Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act S. 1435, Affordable Prescriptions for Patients Act of 2021 H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. H.R. 8920/S. 4760, (116th Congress) The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; Package inserts and labeling issues; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
Client expense: $1,700,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Health Issues
116th Congress S. 1895, The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs; 116th Congress H.R. 19-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing; 116th Congress H.R. 3-Elijah E. Cummings Lower Drug Costs Act Now,--provisions establishing drug pricing and Part D cost sharing; Value-based contracting for pharmaceuticals; 116th Congress H.R. 5304, PBM Transparency in Prescription Drug Costs Act,--provisions related to PBM contracting; education on the value of biosimilars; outreach on PBMs role in social determinants of health and education and outreach on drug patent thickets and other pharmaceutical anticompetitive behavior; S.Con.Res.14 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031 provisions related to drug pricing and a change to the safe harbor rules for drug rebates.
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · first_quarter · Pharmacy
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program S.4796, The Fair Care Act of 2020 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
Client expense: $3,175,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2021 · first_quarter · Health Issues
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.551 - REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319 , American Rescue Plan Act of 2021 H.R. xx - Safe Step Act (no bill number yet) S.4796, The Fair Care Act of 2020 H.R.1966/S.946 - Henrietta Lacks Enhancing Cancer Research Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021, 116th Congress (2019-2020) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
Client expense: $3,175,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2021 · first_quarter · Medicare/Medicaid
H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
Client expense: $3,175,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2021 · second_quarter · Health Issues
Issues related to HR 3 "Lower Drug Costs Now Act of 2019"; issues related to drug pricing; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; issues related to HR 1319 "American Rescue Plan"; general issues related to trade; general issues related to AMP CAP; general issues related to vaccines; issues related to 340B; issues related to insulin pricing; issues related to funding for Pandemic influenza; issues related to Flu Infrastructure Funding; issues related to HR 1978 "Protecting Seniors Through Immunization Act"; issues related to HR 2170 "Helping Adults Protect Immunity Act"; issues related to HR 550 "Immunization Infrastructure Modernization Act"; issues related to HR 2437 "Strengthening the Vaccines for Children Act of 2021"; issues related to HR 3655 "Vaccine Injury Compensation Modernization Act"; issues related to vaccine authorized for emergency use under HR 3705; issues related to RX to OTC switch; issues related to S.1132 "EPI Act"; issues related to S.2164 "Lower Costs, More Cures Act of 2021; and issues related to HR 19 "Lower Costs, More Cures Act of 2021".
Client expense: $980,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Medicare/Medicaid
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Client expense: $450,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse. H.R. 6637, the Health Equity and Accountability Act (HEAA), H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act, S.4264 - U.S. MADE Act of 2020, H.R. 6880 - The Buy American Medical Supplies Act, H.R. 6930 - MADE in America Act, H.R. 3 Lower Drug Costs Now Act of 2019, H.R.1845 - ALERT Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R.748 - CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution. H.R.2503 - The Social Determinants Accelerator Act of 2021, H.R. 3, Drug pricing and transparency, H.R. 16 International price referencing, S.1693 - Medical Supplies for Pandemics Act of 2021, S.65 - Uyghur Forced Labor Prevention Act, H.R. 3173, Improving Seniors Timely Access to Care Act, H.R. 2163 - Safe Step Act
Client expense: $540,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
Maternal Mental Health - Black Maternal Health Momnibus Act of 2021 Seniors Prescription Drug Relief Act Hospital Site of Care Reforms - Two Midnight Rule, Hospital apathy to prioritize maternal mental health Mental Health - pandemic related education and telehealth Medicare Part D Reform - HR.3 and the Prescription Drug Pricing Reduction Act of 2020 21st Century Cures Discussion Draft v.2
Client expense: $275,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Medicare/Medicaid
H.R. 1319, American Rescue Plan Act of 2021, Medicaid provisions and AMP Cap H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019, provisions related to Medicare Part B S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 Issues relating to, Medicaid; Medicare Part B; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; Prior Authorization under Medicare Advantage Plans; FY-2022 Budget and Appropriations Legislation.
Client expense: $1,220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 2061, Advancing Emergency Preparedness Through One Health Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 2076, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. H.R. 8920/S. 4760, (116th Congress) The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; Package inserts and labeling issues; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
Client expense: $1,220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
Legislative issues related to access to pharmaceuticals, including H.R. 3 Lower Drug Costs Now, S. 102 Prescriptions Drug Price Relief Act of 2019, and FY22 Agriculture Appropriations
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
116th Congress S. 1895, The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs ; 116th Congress HR 19-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing; 116th Congress HR 3-Elijah E. Cummings Lower Drug Costs Act Now, --Provisions establishing drug pricing and Part D cost sharing; S. 464/H.R. 2163, Safe Step Act,-Amending ERISA to specify exceptions for medication step therapy; Value-based contracting for pharmaceuticals; 116th Congress H.R. 5304, PBM Transparency in Prescription Drug Costs Act,-provisions related to PBM contracting; S. 164/P.S. 117-8 Advancing Education on Biosimilars Act of 2021-provisions related to an FDA campaign for prescriber education on biosimilars; S. 415/P.L. 117-9, A bill to clarify the meaning of a new chemical entity by the FDA; ; potential suspension of pharmacy audits during the public health emergency and reform of the orphan drug act; measures to combat pharma patent thickets
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · first_quarter · Medicare/Medicaid
H.R. 3: Lower Drug Costs Now Act of 2019 [116th Congress] H.R. 19: Lower Costs, More Cures Act of 2019 [116th Congress] H.R. 1167: Advancing Enrollment and Reducing Drug Costs Act of 2021 - Provisions related to Part D H.R. 1227: Medicare-X Choice Act of 2021 - Provisions related to Part D and non-interference H.R. 1976: To establish an improved Medicare for All national health insurance program - Provisions related to Part D and non-interference H.R. 2010: To amend the Patient Protection and Affordable Care Act to establish a public health insurance option - Provisions related to Part D and non-interference H.R. 2071: To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate covered part D drug prices on behalf of Medicare beneficiaries - Provisions related to Part D and non-interference H.R. 2139: To amend title XVIII of the Social Security Act to provide for the negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D, and for other purposes - Provisions related to Part D and non-interference H.R. 2170: To amend title XIX of the Social Security Act to improve access to adult vaccines under Medicaid - Provisions related to COVID-19 vaccines S. 386: Medicare-X Choice Act of 2021 - Provisions related to Part D and non-interference S. 833: A bill to amend XVIII of the Social Security Act to allow the Secretary of Health and Human Services to negotiate fair prescription drug prices under part D of the Medicare program - Provisions related to Part D and non-interference S. 983: A bill to amend the Patient Protection and Affordable Care Act to establish a public health insurance option, and for other purposes - Provisions related to Part D and non-interference Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Transparency policy issues Alternative payment models policy issues Value-based purchasing arrangements policy issues Anti-Kickback Statute policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Medicaid rebates and waiver policy issues Medicare prescription drug payments cards and related policy issues Final Rule; Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans Calendar Year (CY) 2022 Request for Applications (RFA) for the Part D payment Modernization Model - Part D Formulary Flexibility Final Rule; Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements Final Rule; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Client expense: $1,800,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
2021 · first_quarter · Medicare/Medicaid
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Client expense: $450,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Health Issues
Legislative and administrative monitoring and outreach on healthcare policy. Legislative and administrative monitoring and outreach on prescription drug pricing/PBMs. Legislative and administrative monitoring and outreach on policy issues affecting Medicaid programs. Legislative and administrative monitoring and outreach on the implementation of the Affordable Care Act (ACA) (P.L. 111-148) Legislative and administrative monitoring and outreach on issues regarding the health insurance tax (HIT). Legislative outreach related to executive action surrounding the HHS Rebate rule. S. 4775, Delivering Immediate Relief to America's Families, Schools and Small Businesses Act. Legislative outreach and monitoring the implementation of H.R. 259, Medicaid Extenders Act of 2019 (P.L. 116-3). H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act H.R. 1398, Health Insurance Tax Relief Act of 2019 H.R. 2447, Jobs and Premium Protection Act S. 172, Health Insurance Tax Relief Act of 2019 S. 1895, Lower Health Care Costs Act H.R. 6926, MIND Act H.R. 133, Consolidated Appropriations Act, 2021 (P.L. 116-260). H.R. 1319, American Rescue Plan Act of 2021 (117-2). S. 439, Coronavirus Medicaid Response Act. H.R. 1353, Coronavirus Medicaid Response Act. S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2021. H.R. 955, Medicaid Reentry Act of 2021.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Medicare/Medicaid
H.R. 3 (116th Congress): Elijah E. Cummings Lower Drug Costs Now Act; all provisions of the bill H.R. 1319: American Rescue Plan Act of 2021; all provisions of the bill 2021 Notice of Benefit and Payment Parameters Proposed Rule General healthcare issues surrounding the COVID-19 pandemic
Client expense: $590,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2021 · first_quarter · Health Issues
H.R. 3 (116th Congress): Elijah E. Cummings Lower Drug Costs Now Act; all provisions of the bill H.R. 1319: American Rescue Plan Act of 2021; all provisions of the bill H.R.1957: To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to provide coverage for infertility treatment and standard fertility preservation services, and for other purposes.; all provisions of the bill Centers for Medicare & Medicaid Services (CMS-5528-ANPRM)-Advance Notice of Proposed Rulemaking (ANPRM)-Medicare Program; International Price Index Model for Medicare Part B drugs 2021 Notice of Benefit and Payment Parameters Proposed Rule - 340B Drug Pricing Program policy issues (Draft) 21st Century Cures Act 2.0; all healthcare provisions of the draft General discussions regarding support for, and importance of, care-giving General healthcare issues surrounding the COVID-19 pandemic General issues surrounding healthcare supply chain General discussions regarding drug cost and pricing policy issues General discussions regarding Most Favored Nations/International Price Index Model for Medicare Part D drugs
Client expense: $590,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2021 · first_quarter · Pharmacy
H.R. 3 (116th Congress): Elijah E. Cummings Lower Drug Costs Now Act; all provisions of the bill H.R. 1319: American Rescue Plan Act of 2021; all provisions of the bill General healthcare issues surrounding the COVID-19 pandemic General issues surrounding healthcare supply chain
Client expense: $590,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2021 · first_quarter · Health Issues
CMS-9115-P Interoperability and Patient Access Final Rule HHS ONC RIN-0955-AA01 - 21st Century Cures Interoperability and Information Blocking Final Rule H.R. 3, Lower Drug Costs Now Act of 2019 (116th Congress) S. 2543, Prescription Drug Pricing Reduction Act of 2019 (116th Congress) S. 3129, Lower Cost, More Cures Act of 2019 (116th Congress) H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act S. 4775, Delivering Immediate Relief to Americas Families, Schools and Small Business Act COVID-19 Response, including COVID-19 bills legislation implementation The Senate Amendment to H.R. 133, Consolidated Appropriations Act, 2021 (surprise billing legislation implementation) H.R. 1319, American Rescue Plan Act of 2021; P.L. 117-2 H.R. 19, Lower Cost, More Cures act of 2019 (116th Congress)
Client expense: $1,080,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
AMP Cap Anti-Kickback Statute policy issues ASP reporting policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Drug Pricing Drug wastage rebates policy issues Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Medicaid Medicaid rebates and waiver policy issues Medicare Part A, B and D Outcomes based Contracting/value based arrangements Patient Cost-Sharing and Smoothing Reimbursement for cell therapy products Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals Transparency policy issues Tenncare III 1115 Medicaid Demonstration - Closed formulary issues S.2543: Prescription Drug Pricing Reduction Act of 2019 [116th Congress] H.R. 3: Lower Drug Costs Now Act of 2019 [116th Congress] H.R. 19: Lower Costs, More Cures Act of 2019 [116th Congress] S. 386/H.R. 1227: Medicare-X Choice Act of 2021
Client expense: $2,170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
2021 · first_quarter · Health Issues
Issues related to HR 3 "Lower Drug Costs Now Act of 2019"; issues related to drug pricing, issues related to COVID vaccine development; issues related to vaccine confidence; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; issues related to HR 1319 "American Rescue Plan"; general issues related to trade; general issues related to AMP CAP; general issues related to vaccines.
Client expense: $1,440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Health Issues
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse. H.R. 6637, the Health Equity and Accountability Act (HEAA), H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act, S.4264 - U.S. MADE Act of 2020, H.R. 6880 - The Buy American Medical Supplies Act, H.R. 6930 - MADE in America Act, H.R. 3 Lower Drug Costs Now Act of 2019, H.R.1845 - ALERT Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R.748 - CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution
Client expense: $530,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE